Yesterday, Reata Pharmaceuticals (RETA) reported the first topline results from its CARDINAL Phase 3 Bardoxolone trial. This is a trial for the use of Bardoxolone on Alport Syndrome. Alport is one of many genetic and environmental conditions leading to ESRD (End-Stage Renal Disease) requiring dialysis or kidney transplantation. Dialysis is typically the largest single cost health systems face.
The results were very positive. Bardoxolone achieved the primary and secondary endpoints. Most importantly, Bardoxolone did not show increased cardiovascular risk, as it had in the past – in a way that made a